EAEventAlpha
Tech / AI

FDA approves Retatrutide this year?

14%Synced 4 Jul 2026, 03:01 UTCStable consensus

Market activity is moderate — moves should be interpreted with standard caution.

Signal: Medium

Current

14%

24h Change

-0.5pp

7D Change

Not enough history

30D Change

Not enough history

Snapshots

8

0%25%50%75%100%30 Jun3 Jul4 Jul

Movement Read

This page helps you check whether the move is fresh, meaningful, low-confidence, or near resolution before opening the source market.

24h probability change is not available. Treat current pricing as a snapshot until more history accumulates.

Market Snapshot — read-only

Implied probabilities from synced Polymarket data. EventAlpha does not support trading.

Yes implied probability
14.0%
No implied probability
86.0%
Liquidity
$5K
Market Activity
$575K
Data Source
Polymarket
Last Synced
4 Jul 2026, 03:01 UTC
View on Polymarket

Resolution Rules

Resolves Yes if …

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

Resolves No if …

No otherwise — if the Yes condition is not satisfied by the resolution criteria.

Important caveats

This market resolves according to the source market rules. Review the source market before relying on this interpretation.

Resolution deadline: 31 Dec 2026, 00:00 UTC

More in Tech/AI

Same category markets without strong topical overlap.

No closely related markets found — showing broader Tech/AI markets instead.